95 related articles for article (PubMed ID: 6957624)
1. Improved prospects for long-term survival in adults with acute myelogenous leukemia.
Keating MJ; McCredie KB; Bodey GP; Smith TL; Gehan E; Freireich EJ
JAMA; 1982 Nov; 248(19):2481-6. PubMed ID: 6957624
[TBL] [Abstract][Full Text] [Related]
2. A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia.
Keating MJ; Smith TL; McCredie KB; Bodey GP; Hersh EM; Gutterman JU; Gehan E; Freireich EJ
Cancer; 1981 Jun; 47(12):2779-88. PubMed ID: 6942906
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival in acute leukemia. Twenty-two adult patients surviving for over five years.
Evensen SA; Stavem P
Acta Med Scand; 1986; 219(1):79-83. PubMed ID: 3456695
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in response to anthracyclines.
McCredie KB; Keating MJ; Bodey GP; Gehan EA; Smith T; Freireich EJ
Cancer Treat Rep; 1981; 65 Suppl 4():83-6. PubMed ID: 6955014
[No Abstract] [Full Text] [Related]
5. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
6. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Ghaddar HM; Plunkett W; Kantarjian HM; Pierce S; Freireich EJ; Keating MJ; Estey EH
Leukemia; 1994 Aug; 8(8):1269-74. PubMed ID: 8057660
[TBL] [Abstract][Full Text] [Related]
7. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
[TBL] [Abstract][Full Text] [Related]
8. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
9. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
[TBL] [Abstract][Full Text] [Related]
10. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
12. [Clinical observations of 30 patients with acute promyelocytic leukemia].
Chang CS; Chen JR; Lin SF; Liu HW; Yen JH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1986 Oct; 2(10):608-15. PubMed ID: 3330141
[No Abstract] [Full Text] [Related]
13. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
14. [Full remission of acute non-lymphatic leukemia lasting for 16 months following combination therapy with aclacinomycin A].
Beck JD
Monatsschr Kinderheilkd; 1986 Aug; 134(8):547-9. PubMed ID: 3464845
[TBL] [Abstract][Full Text] [Related]
15. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
Wiedower E; Jamy O; Martin MG
Anticancer Res; 2015 Nov; 35(11):6287-90. PubMed ID: 26504064
[TBL] [Abstract][Full Text] [Related]
16. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.
Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
Leukemia; 1992 Nov; 6(11):1189-91. PubMed ID: 1434803
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.
Vogler WR; Preisler HD; Winton EF; Gottlieb AJ; Goldberg J; Brennan J; Grunwald H; Rai K; Browman G; Miller KB
Cancer Treat Rep; 1986 Apr; 70(4):455-9. PubMed ID: 3516395
[TBL] [Abstract][Full Text] [Related]
18. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
Mayer RJ; Davis RB; Schiffer CA; Berg DT; Powell BL; Schulman P; Omura GA; Moore JO; McIntyre OR; Frei E
N Engl J Med; 1994 Oct; 331(14):896-903. PubMed ID: 8078551
[TBL] [Abstract][Full Text] [Related]
19. Therapy of acute myelogenous leukemia: results of combination chemotherapy with cytarabine, daunorubicin and 6-mercaptopurine.
Ko WS; Chen LM; Hwang SH; Chao TY; Wang CC; Kao WY; Lee WC; Hwang WS
Zhonghua Yi Xue Za Zhi (Taipei); 1991 Sep; 48(3):185-9. PubMed ID: 1657335
[TBL] [Abstract][Full Text] [Related]
20. [Long-term treatment and prognostic factors in adult acute myeloblastic leukemia. Experience of the INNSZ group Puebla-Monterrey-Mexico)].
Lobato-Mendizabal E; Ruiz-Argüelles GJ; Gómez-Almaguer D; Ganci-Cerrud G; Lozano de la Vega A; Labardini-Méndez J
Rev Invest Clin; 1991; 43(3):215-22. PubMed ID: 1818368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
